Investment Rating - The industry investment rating is maintained at "Overweight" [2][9]. Core Insights - The vaccine industry is experiencing a transition from scale expansion to innovation-driven growth, with short-term pain due to supply-demand imbalance and homogenized competition, but the long-term positive outlook remains unchanged [9][27]. - Recent advancements in vaccine technology and policy changes are expected to drive demand, particularly with the expansion of the immunization program for Japanese encephalitis vaccines in certain regions [4][9]. - Companies like Zhifei Biological are making significant progress with new vaccine candidates, including an mRNA vaccine for shingles and a lyophilized inactivated vaccine for chickenpox, which could enhance their competitive edge [4][9]. Summary by Sections Industry Performance - The vaccine sector has seen a cumulative decline of 11.36% since 2025, with a recent weekly drop of 1.42% [5][11]. - Relative performance against the CSI 300 index shows a decline of 29% over the past 12 months [4]. Company Developments - Zhifei Biological has received clinical trial approval for two new vaccines, indicating progress in both mRNA and inactivated vaccine technologies [4]. - The company is focusing on innovative vaccine development to enhance its product pipeline and market competitiveness [9]. Market Dynamics - The vaccine industry is currently facing challenges such as high competition among Me-too products and a decline in demand due to consumer hesitancy [8][24]. - The industry is expected to adjust its pipeline strategies, emphasizing innovation and multi-valent products to improve market positioning [8][24]. Valuation Metrics - The vaccine sector's price-to-earnings (PE) ratio is reported at 65.37X, with a recent decrease of 1.47X, while the price-to-book (PB) ratio stands at 1.21X [7][19]. - The PE ratio is at the 55.06% percentile since 2013, indicating a relatively high valuation compared to historical data [7]. Investment Recommendations - The report suggests focusing on companies with strong research and innovation capabilities, particularly those with differentiated product offerings, such as CanSino [9][27]. - Long-term investment opportunities are anticipated in the context of innovation and international market expansion [8][9].

Core Viewpoint - The company has achieved a significant technological breakthrough with its serum-free iterative rabies vaccine, which is expected to fill a market gap as it is the first of its kind to be approved for sale globally [1][2] Group 1: Product Development and Approval - The company's subsidiary, Aimeirongyu (Ningbo) Biopharmaceutical Co., Ltd., has successfully passed the clinical trial site inspection and drug registration production site inspection for its serum-free iterative rabies vaccine [1] - The Phase III clinical study results indicate that the vaccine demonstrates good safety, immunogenicity, and durability, meeting all preset evaluation standards [1] - The company has obtained the necessary production license for the serum-free iterative rabies vaccine, positioning itself for a market launch [1] Group 2: Market Potential and Competitive Advantage - China is the largest rabies vaccine market globally, projected to reach 14.8 billion yuan by 2030, driven by product updates and increased vaccine adoption [2] - The new vaccine's lack of animal serum significantly enhances safety and reduces the likelihood of adverse reactions, making it a preferred choice for vaccination institutions [2] - As the second-largest supplier of rabies vaccines globally, the company aims to lead in the deep technological iteration and upgrade of rabies vaccines, with the capability for large-scale production once the product is approved [2]